While mesenchymal-epithelial transition factor (MET) amplification is a rare mutation, occurring in only 1%–5% of stage IV driver-positive NSCLC patients (Fujino et al., 2020), it is significant in terms of targeted therapy (Fujino et al., 2020). Here, MET is linked to non-small cell lung carcinoma.